The therapeutic effects of edaravone on collagen‐induced arthritis in rats

Zhang, Xiaohan; Ye, Guihong; Wu, Zhengyuan; Zou, Kai; He, Xinrong; Xu, Xiangsheng; Yao, Jun; Wei, Qingjun

doi:10.1002/jcb.29382

Cited by 12 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has pointed out that GADD45B, a homologous gene of GADD45A, is involved in the regulation of early osteoarthritis (Shimada et al, 2016). Changes in the expression level of GADD45A can affect the expression of NF-κB in collagen-induced arthritis and thereby affect the treatment of arthritis (Zhang et al, 2020c), which may provide a new direction for the treatment of bone and joint disease.…”

Section: Discussionmentioning

confidence: 99%

Candidate Marker Genes for Diagnosis of Osteoarthritis and Prediction of Their Regulatory Mechanisms

Zhang,

Liu,

Xiong

et al. 2023

Fol. Biol.

View full text Add to dashboard Cite

We have screened candidate marker genes for the diagnosis of osteoarthritis and predicted their regulatory mechanisms. Six expression chips of tissue samples and one expression chip of peripheral blood mononuclear cell (PMBC) samples were obtained from the GEO database. Differential analysis, GSEA, and WGCNA were performed on the integrated tissue sample data with batch correction. Candidate genes were obtained from the intersection of the genes significantly related to osteoarthritis in the WGCNA and the differentially expressed genes. ROC analysis was performed on the candidate genes in the tissue and PMBC samples. Genes with AUC values greater than 0.6 were retained as final candidates, and their upstream regulatory miRNAs were predicted. A total of 106 genes with differential expression were found in osteoarthritis tissue samples, which were mainly enriched in cell cycle and p53 signalling pathways. WGCNA selected a gene module significantly correlated with the occurrence of osteoarthritis. Fourteen candidate genes were obtained from the intersection of the genes in the module and the differentially expressed genes. ROC analysis showed that among these 14 candidate genes, only ADM, CX3CR1 and GADD45A had AUC values greater than 0.6 in both tissue and PMBC samples. The AUC values of the gene set of these three genes were greater than 0.7. Multiple miRNAs were predicted to be regulators of these three genes. ADM, CX3CR1 and GADD45A have potential as diagnostic marker genes for osteoarthritis and may be regulated by multiple miRNAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Candidate Marker Genes for Diagnosis of Osteoarthritis and Prediction of Their Regulatory Mechanisms

Zhang,

Liu,

Xiong

et al. 2023

Fol. Biol.

View full text Add to dashboard Cite

show abstract

“…Hypoxia, ischemia, and blood supply disorders in local brain tissues can activate microglia and peripheral white blood cells, resulting in a series of inflammatory reactions in the body and aggravating the damage of brain tissues and peripheral neurons. A previous study [23] has shown that inflammatory factors such as IL-6, IL-8, and hs-CRP can promote the formation of thrombosis, among which hs-CRP is an important indicator reflecting atherosclerosis and acute inflammatory response. In this study, after edaravone combined with anticoagulant therapy was adopted, the serum inflammatory factor levels in the combined group after treatment were notably lower than those in the routine group (P < 0.001), suggesting that the combined therapy can effectively alleviate the inflammatory response of ACI patients and then delay the disease progression.…”

Section: Discussionmentioning

confidence: 99%

Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-α Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction

Sun

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-α levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). Methods. The clinical data of 84 ACI patients treated in our hospital from August 2020 to August 2021 were retrospectively analyzed, and they were divided into the routine group (n = 42) and the combined group (n = 42) according to the order of admission. Both groups were treated with routine clinical treatment, and the combined group was additionally treated with edaravone combined with anticoagulant therapy. Serum samples were collected from both groups after treatment. ELISA was used to detect the serum inflammatory factor levels, and the modified Barthel index score was used to evaluate the ADL of patients. Results. Compared with the routine group, the combined group achieved obviously lower levels of PMA, CD62p, and serum inflammatory factors after treatment ( P < 0.001 ), higher modified Barthel score after treatment ( P < 0.001 ), lower plasma viscosity, platelet aggregation rate, and plasma fibrinogen level after treatment ( P < 0.001 ), and higher clinical overall efficacy ( P < 0.05 ). Conclusion. Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients. This strategy greatly reduces the platelet-activating factor levels of patients and improves the comprehensive clinical efficacy, and its further research will help to establish a better solution for these patients.

show abstract

“…Edaravone can reduce the concentration of eNOS, heme oxygenase-1, perisynovial ROS production and inflammatory factors. Edaravone has been shown to reduce the expression of NF-κB p65 by scavenging ROS and alleviates tissue damage and arthritis symptoms [77]. The phosphodiesterase (PDE) inhibitors Vardenafil and cilostazol can induce vasodilation and maintain endothelial integrity.…”

Section: Conventional Dmardsmentioning

confidence: 99%

Nitric Oxide Synthases in Rheumatoid Arthritis

et al. 2023

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by severe joint damage and disability. However, the specific mechanism of RA has not been thoroughly clarified over the past decade. Nitric oxide (NO), a kind of gas messenger molecule with many molecular targets, is demonstrated to have significant roles in histopathology and homeostasis. Three nitric oxide synthases (NOS) are related to producing NO and regulating the generation of NO. Based on the latest studies, NOS/NO signaling pathways play a key role in the pathogenesis of RA. Overproduction of NO can induce the generation and release of inflammatory cytokines and act as free radical gas to accumulate and trigger oxidative stress, which can involve in the pathogenesis of RA. Therefore, targeting NOS and its upstream and downstream signaling pathways may be an effective approach to managing RA. This review clearly summarizes the NOS/NO signaling pathway, the pathological changes of RA, the involvement of NOS/NO in RA pathogenesis and the conventional and novel drugs based on NOS/NO signaling pathways that are still in clinical trials and have good therapeutic potential in recent years, with an aim to provide a theoretical basis for further exploration of the role of NOS/NO in the pathogenesis, prevention and treatment of RA.

show abstract

The therapeutic effects of edaravone on collagen‐induced arthritis in rats

Cited by 12 publications

References 27 publications

Candidate Marker Genes for Diagnosis of Osteoarthritis and Prediction of Their Regulatory Mechanisms

Candidate Marker Genes for Diagnosis of Osteoarthritis and Prediction of Their Regulatory Mechanisms

Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-α Levels and Activity of Daily Living in Patients with Acute Cerebral Infarction

Nitric Oxide Synthases in Rheumatoid Arthritis

Contact Info

Product

Resources

About